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Persistence (therapy duration) was defined as number of days between the first and 
last available medication. Adherence was assessed using the medication possession 
ratio (MPR), defined as the number of days with statin therapy on hand divided by 
duration of statin therapy. Results: A total of 3,417 patients met the inclusion 
criteria. The most common statins received were atorvastatin (32.43%), rosuvas-
tatin (22.21%), and pravastatin (20.00%). At initiation, mean(SD) dose (mg/day) was 
9.00(3.66) for atorvastatin, 2.97(1.50) for rosuvastatin, and 9.12(3.09) for pravastatin. 
The percentage of patients with dose titration was low (range: 1.02% for simvastatin 
to 5.01% for rosuvastatin). Mean(SD) persistence ranged from 460.77(270.26) days 
for fluvastatin to 540.08(247.51) days for atorvastatin. Mean(SD) MPR ranged from 
0.90(0.16) for rosuvastatin to 0.95(0.11) for fluvastatin. When MPR was alternatively 
measured over the entire 24 month follow-up period, mean(SD) MPR ranged from 
0.75(0.29) for rosuvastatin to 0.80(0.26) for fluvastatin. ConClusions: Statin titra-
tion among Japanese patients with HRVD was rare, and most patients remained on 
the lowest dosage available during follow-up. Although statin adherence was good, 
these findings raise potential concerns about under-treatment/under-management 
of HRVD in Japan.
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objeCtives: The purpose of this study was to assess patterns and predictors of 
warfarin persistence, discontinuation, and interruption among patients with non-
valvular atrial fibrillation (NVAF). Methods: This study used the MarketScan 
Database and included patients (≥ 18 years of age) with NVAF who were initiated 
on warfarin and followed for 365 days. Persistence was defined as warfarin therapy 
without a gap > 45 days between warfarin prescriptions. Interruption was defined as 
a gap in warfarin therapy > 45 days and ≤ 90 days and discontinuation was defined 
as > 90 days without warfarin therapy. Factors associated with warfarin interrup-
tion/discontinuation were determined using a Cox proportional hazards regres-
sion model. Sensitivity analyses were conducted to assess robustness of results 
by shifting prescription gaps by 7, 14, and 30 days. Results: Within 12 months 
of warfarin initiation, 26,241 (44.8%) patients were persistent with warfarin, 6,895 
(11.8%) had interruption, and 25,457 (43.4%) had discontinuation with or without 
interruption. The risk of warfarin interruption or discontinuation was significantly 
greater in patients that were younger than 65 years (hazard ratio [HR]: 1.22; 95% 
confidence interval [CI]: 1.19-1.25), lived in the West (HR: 1.07; 95% CI: 1.03-1.11), had 
anemia (HR: 1.10; 95% CI: 1.06-1.14), experienced bleeding episodes (HR: 1.10; 95% CI: 
1.06-1.14), were hospitalized or had emergency room visits (HR: 1.11; 95% CI: 1.08-
1.13), or had higher Charlson Comorbidity Index (HR: 1.01; 95% CI: 1.01-1.02). The 
significant factors associated with interruption/discontinuation were consistent 
in the sensitivity analyses. ConClusions: In the usual clinical practice setting, 
more than 50% of patients discontinued or interrupted warfarin within one year 
after initiation. Age < 65 years, multiple medical conditions, and previous hospital 
and ER visits were associated with increased risk of interruption/discontinuation. 
Given the prevalence of warfarin discontinuation/interruption, health care provid-
ers should take a more active role in understanding and addressing the reasons 
behind patient non-persistence.
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objeCtives: The polypharmacy were incidence increase risk of drug-drug interac-
tions, especial suffers from elderly and chronic disease such as age greater than 
60 years old, chronic kidney dysfunction, cardiovascular disease and cancers are 
significant. To evaluate the cost-effectiveness of consultations by pharmacists 
based within primary care polypharmacy in chronic disease. Methods: In order to 
avoid duplication and waste treatment drugs, the plan is to be Pharmaceutical Care 
System and to search medication information at Department of National Health 
Insurance Virtual Private Cloud (VPC). We were identifying potential duplicate medi-
cation from patients with polypharmacy, and to evaluated pharmacist consultations 
on health service use outcome. The study subjects were identified based on inap-
propriate prescriptions of duplicate medications, drug-drug interactions, or over-
dosage. Chi-square test was used for pharmacist consultations on health service 
and cost-effectiveness of data analysis. Results: A total of 68 patients on health 
service with pharmacist consultations were included in this study. The total direct 
medical costs for 24 patients were NT$3,4480 dollars and improved polypharmacy 
related adverse reaction. ConClusions: To develop pharmacist consultations on 
health service is helpful of increase communication and interaction with the pro-
fessional skills of pharmacists and physicians to achieve consensus professional 
and is likely to save costs.
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objeCtives: To determine the quality of life of the patients who underwent angi-
oplasty patients. Methods: This was an open labeled, randomized control trial 
conducted at Kasturba Hospital, Manipal, Karnataka, India. Patients admitted in 
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objeCtives: To study the association between baseline socio-demographic and 
clinical characteristics and total annual follow up cost of unselected patients sub-
jected CRMDs implantation in a real-world setting. Methods: A single-centre, 
prospective study was conducted for one year’s period. In total, 464 consecutive 
patients were recruited (370 were subjected to PM implantation initial or replace-
ment and 94 to ICD implantation initial or replacement). The baseline collected data 
encompasses: socio-demographic characteristics, measurements of anthropometric 
and clinical characteristics; medical history, medications used before the enrolment 
in the study and QoL assessed by the EUROQOL EQ-5D Questionnaire. Resource 
data were assessed at 6 and 12 months after the procedure of implantation. Then, 
the components of cost were calculated using the bottom-up approach. Results: 
The generalized linear model indicated that among the variables considered, only 
age, history of hypertension and hypercholesterolaemia are significantly associ-
ated with the total annual social cost of patients subjected to PM implantation. 
The predicted mean total annual costs (95% CI) adjusted for the factors mentioned 
above were € 2.256 (€ 2.018–€ 2.534) for the overall sample of PM patients, and € 2.171 
(€ 1.888–€ 2.505) and € 2.409 (€ 2.063–€ 2.778) in patients with initial PM implantation 
and those subjected to PM replacement, respectively. In addition, the history of 
hypertension and hypercholesterolaemia as well as the baseline QoL were signifi-
cantly associated with the total annual cost of patients subjected to ICD implan-
tation. The predicted mean total annual costs (95% CI) adjusted for the factors 
mentioned above were € 3.318 (€ 2.771–€ 3.967) for the overall sample of ICD patients, 
and 3.528 (€ 2.901– € 4.156) and € 2.044 (€ 1.329–€ 3.029) in patients with initial ICD 
implantation and those subjected to ICD replacement, respectively. ConClusions: 
Age, history of hypertension and hypercholesterolaemia for the patients were sub-
jected to PM implantation and moreover the quality of life for the patients were 
subjected to ICD are significantly associated with the total annual social cost.
CarDioVasCular DisorDers – Patient-reported outcomes & Patient  
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objeCtives: Uncontrolled blood pressure (BP) attributed to medication non-adher-
ence may increase the risk of complications and death. Predicting hypertensive 
patients’ medication adherence, therefore, is an important factor. The theory of 
planned behavior (TPB) proposes that the hypertensive patient’s attitude, subjective 
norm, and perceived behavioral control predict intention to perform behavior, leading 
to prediction of medication adherence. Methods: 604 outpatients with established 
chronic hypertension from a regional hospital in eastern Taiwan were enrolled in this 
study. Using a cross-sectional study, BP was measured and structured questionnaires 
were delivered to all participants. Descriptive statistics were calculated for all meas-
ures as appropriate. To assess differences among the adherence and poor adherence 
groups by demographic, TPB variables and BP, Chi-Square test and Fisher’s exact test 
for categorical variables or analysis of variance tests for continuous variables were 
performed. The medication adherence, TPB variables and BP were analyzed using 
correlation coefficient. All data were analyzed using SPSS 20.0 statistical analysis 
software. Results: The mean of adherence scores was 2.6 (sd= 2.4). Adherence and 
poor adherence of patients accounted for 57.5% and 42.5%, respectively. Intention was 
positively correlated with attitude (r= 0.23, p= 0 .00), subjective norm (r= 0.27, p= 0 .00), 
and perceived behavior control (r= 0.53, p= 0 .00). Adherence was positively correlated 
with intention (r= 0.49, p= 0 .00). When SBP and DBP were considered separately, 
adherence was significantly different between the good and poor controls of SBP and 
DBP. The two adherence groups were positively correlated with SBP control (r= 0.09, 
p= 0 .02) and DBP control (r= 0.10, p= 0.01). ConClusions: Hypertensive patients’ 
attitudes, subjective norms, and perceived behavioral controls predict intentions, 
leading to prediction of medication adherence. Medication adherence has significant 
impact on the SBP and the DBP control. These results suggest that application of TPB 
is useful to predict medication adherence in Taiwanese patients.
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objeCtives: To document dose titration, persistence, and adherence among 
patients with high-risk vascular disease (HRVD) receiving statin therapy in an 
employed Japanese population. Methods: A retrospective analysis was con-
ducted using the Japan Medical Data Center (JMDC) database, which contained 
inpatient, outpatient, and pharmacy claims of 800,000 lives from 2006–2011. HRVD 
was identified based on diagnoses for cerebrovascular disease, peripheral artery 
disease, coronary artery disease with diabetes, and history of acute coronary syn-
drome (ACS) (with an ACS claim > 30–≤ 365 days after ACS-related hospitalization) 
between 1/1/2008–12/31/2009. Patients were required to have insurance coverage 
for ≥ 12 months before and ≥ 24 months after first HRVD claim. Patients receiving 
statin therapy were selected to assess dose titration, persistence, and adherence. 
